FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 540 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR When Used Together, Chemo and Cardiac Drug Improve Chances of Cancer... December 17, 2021 Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... April 26, 2022 A recipe for hydration! August 7, 2020 Researchers Find New, Effective Tools to Determine Breast Cancer Risk Using... December 29, 2020 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Zanubrutinib FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... Getting cancer services back on track during the COVID-19 pandemic
